With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK expects 2025 sales growth between 3% and ... Emily Field, Barclays: Asked about Shingrix's performance in China and the impact of macroeconomic challenges. Chief Commercial Officer Luke ...

GSK’s vaccine sales in China reflect broader pressures facing multinational pharma firms in the Chinese market. In December 2024, GSK’s Chinese distribution deal for Shingrix with Chongqing ...